| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Steven Simoens | Q87433253 |
| Isabelle Huys | Q90765106 | ||
| Arnold G Vulto | Q90785935 | ||
| Liese Barbier | Q93139733 | ||
| Paul Declerck | Q38362910 | ||
| P2093 | author name string | Patrick Neven | |
| P2860 | cites work | Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies | Q26738325 |
| Biosimilars: Extrapolation for oncology | Q26746241 | ||
| Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options | Q26777681 | ||
| Expert perspectives on biosimilar monoclonal antibodies in breast cancer | Q26865410 | ||
| Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets | Q34309684 | ||
| Biosimilars: the science of extrapolation | Q34442570 | ||
| A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). | Q34635509 | ||
| A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects. | Q51669281 | ||
| HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. | Q53097008 | ||
| Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. | Q54135887 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. | Q55008089 | ||
| Biosimilars lining up to compete with Herceptin--opportunity knocks. | Q55070708 | ||
| Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer | Q57108415 | ||
| Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial | Q57110471 | ||
| Trastuzumab in the treatment of breast cancer | Q81374982 | ||
| Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching | Q88486794 | ||
| Scientific Evidence and Financial Obligations to Ensure Access to Biosimilars for Cancer Treatment | Q88905485 | ||
| Can we establish a hierarchy among trastuzumab biosimilar candidates? | Q90010789 | ||
| Worldwide experience with biosimilar development | Q34974791 | ||
| The economic pressures for biosimilar drug use in cancer medicine | Q35795204 | ||
| Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial | Q36558836 | ||
| A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer | Q36706854 | ||
| Key drivers for market penetration of biosimilars in Europe. | Q37669625 | ||
| The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects | Q37732903 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline | Q38209628 | ||
| New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer | Q38300338 | ||
| Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. | Q38383854 | ||
| Statistical Primer on Biosimilar Clinical Development | Q38696351 | ||
| Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars | Q38753372 | ||
| Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar | Q38906179 | ||
| The design of clinical trials to support the switching and alternation of biosimilars | Q38963970 | ||
| Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. | Q39138759 | ||
| CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial | Q39358281 | ||
| A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers | Q40183869 | ||
| Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy | Q41930681 | ||
| Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians | Q42013744 | ||
| The road from development to approval: evaluating the body of evidence to confirm biosimilarity | Q47950956 | ||
| Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive | Q49662502 | ||
| A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. | Q49968542 | ||
| The process defines the product: what really matters in biosimilar design and production? | Q50115805 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | trastuzumab | Q412616 |
| monoclonal antibody | Q422248 | ||
| biosimilar | Q864715 | ||
| neoplasm | Q1216998 | ||
| P304 | page(s) | 199-210 | |
| P577 | publication date | 2019-07-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars | |
| P478 | volume | 121 |
Search more.